Prosecution Insights
Prosecution Insights
Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Larimar Therapeutics Inc. has 1 pending office action in the Chemistry & Materials technology area. This action is assigned to 1 distinct examiner, Rebecca M Fritchman, indicating a highly focused prosecution phase for this portfolio. With only 1 pending office action total, the company's current patent prosecution is very centralized. This suggests a specific technical objective within the chemistry and materials sector rather than a broad array of filings.
Rebecca M Fritchman is the busiest examiner for the company, managing 1 busiest examiner pending action. The prosecution is located in 1 distinct art unit. This concentration in 1 distinct art unit suggests that the company's current intellectual property efforts are focused on a specific chemistry innovation. Because the total workload is limited to 1 distinct art unit, practitioners can focus their technical arguments on the specific standards of that unit. The fact that Rebecca M Fritchman handles the only 1 pending office action means that the relationship with this examiner is the primary factor in the company's current patent success.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRITCHMAN, REBECCA M | 1 | 45.7% | +35.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18315445 | FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY | FRITCHMAN, REBECCA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18315445 | FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY | FRITCHMAN, REBECCA M | — |
| Art Unit | Apps |
|---|---|
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18315445 | FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY | FRITCHMAN, REBECCA M | 1758 | §101§103§112 | Non-Final OA | — | Pending | May 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial